Skip to main content

Table 1 Treatment and imaging for each group

From: Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies

Group

Number of mice

Treatment

Imaging

177Lu-TATE

4

50 MBq 177Lu-TATE i.v.

6 × MRI, 1 × SPECT/CT

TMZ

7

TMZ 50 mg/kg p.o. for 14 days

7 × MRI, 7 × SPECT/CT

Control

3

Saline

3 × MRI

  1. 177 Lu-TATE lutetium-177-labelled octreotate, TMZ temozolomide